公开(公告)号：US09657103B2

公开(公告)日：2017-05-23

申请号：US14398293

申请日：2013-03-15

Applicant: NEW YORK UNIVERSITY

Inventor： Victor J. Torres ,  Ashley L. Dumont

IPC: A61K39/395 ,  C07K16/28 ,  C07K14/31 ,  C07K14/435 ,  C07K14/705 ,  A61K38/17 ,  A61K45/06 ,  C07K14/47 ,  G01N33/569 ,  A61K39/00

CPC classification number: C07K16/2845 ,  A61K38/1741 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K14/31 ,  C07K14/4354 ,  C07K14/473 ,  C07K14/70553 ,  C07K2317/76 ,  C07K2319/21 ,  G01N33/56938

Abstract: The present invention relates to methods of treating and preventing Staphylococcus aureus infection and/or a condition resulting from a S. aureus infection a subject that involves administering a CD11b inhibitor. The present invention further relates to a non-human transgenic animal expressing human CD11b and its use in methods of identifying novel therapeutics for the treatment and prevention of Staphylococcus aureus infection and/or a condition resulting from a S. aureus infection.

公开(公告)号：US09642904B2

公开(公告)日：2017-05-09

申请号：US14961772

申请日：2015-12-07

Applicant: GlaxoSmithKline Biologicals SA

Inventor： Fabio Bagnoli ,  Massimiliano Biagini ,  Luigi Fiaschi ,  Guido Grandi ,  Ravi Pratap Narayan Mishra ,  Nathalie Norais ,  Maria Scarselli

IPC: A61K39/085 ,  C07K14/31 ,  A61K39/00

CPC classification number: A61K39/085 ,  A61K39/00 ,  C07K14/31 ,  C07K2319/00

Abstract: An effective Staphylococcus aureus vaccine may require several antigenic components, and so various combinations of S. aureus antigens are identified for use in immunisation. These polypeptides may optionally be used in combination with S. aureus saccharides.

公开(公告)号：US09567379B2

公开(公告)日：2017-02-14

申请号：US13260878

申请日：2010-04-05

Applicant: Olaf Schneewind ,  Alice Cheng ,  Dominique M. Missiakas ,  Hwan Keun Kim

Inventor： Olaf Schneewind ,  Alice Cheng ,  Dominique M. Missiakas ,  Hwan Keun Kim

IPC: A61K39/00 ,  A61K39/02 ,  A61K39/09 ,  A61K39/085 ,  C07K14/31

CPC classification number: C07K14/31 ,  A61K39/00 ,  A61K39/085

Abstract: Disclosed are methods and compositions for treating or preventing a Staphylococcus bacterial infection using a non-toxigenic Protein A (SpA) variant.

Abstract translation: 公开了使用非产毒蛋白A（SpA）变体治疗或预防葡萄球菌细菌感染的方法和组合物。

公开(公告)号：US09534022B2

公开(公告)日：2017-01-03

申请号：US14802602

申请日：2015-07-17

Applicant: Evaxion Biotech ApS

Inventor： Niels Iversen Møller ,  Andreas Holm Mattsson

IPC: A61K39/085 ,  C07K14/31 ,  C07K16/12 ,  C12Q1/68 ,  A61K39/00

CPC classification number: A61K39/085 ,  A61K2039/505 ,  A61K2039/545 ,  A61K2039/55 ,  A61K2039/55505 ,  A61K2039/6081 ,  C07K14/31 ,  C07K16/1271 ,  C07K2317/34 ,  C12Q1/689 ,  C12Q2600/158

Abstract: Disclosed are novel immunogenic proteins derived from Staphylococcus aureus, as well as methods for their use in conferring protective immunity against S. aureus infections. Also disclosed are nucleic acids encoding the proteins and methods of use of these nucleic acids.

Abstract translation: 公开了衍生自金黄色葡萄球菌的新型免疫原性蛋白质，以及它们用于赋予金黄色葡萄球菌感染的保护性免疫的方法。 还公开了编码蛋白质的核酸和这些核酸的使用方法。

公开(公告)号：US09447403B2

公开(公告)日：2016-09-20

申请号：US14045433

申请日：2013-10-03

Applicant: Merck Sharp & Dohme Corp.

Inventor： Tessie B. McNeely ,  Leslie Cope ,  Sharon Smith ,  Amita Joshi ,  Irene Pak ,  Arthur Fridman

IPC: C07K14/31 ,  A61K39/085 ,  C12N9/88 ,  A61K38/00 ,  A61K39/00

CPC classification number: C12N9/88 ,  A61K38/00 ,  A61K39/085 ,  A61K2039/55505 ,  A61K2039/6037 ,  C07K14/31

Abstract: The present invention relates to peptides of the enolase protein from Staphylococcus aureus as well as nucleic acid and nucleic acid sequence homologs encoding the peptides. The present invention also relates to a composition, particularly a S. aureus vaccine, comprising one or more of the enolase peptides described herein or a fragment, derivative or variant thereof capable of generating an immune response that induces a protective antibody response or opsonophagocytic activity of human neutrophils for S. aureus. The present invention also encompasses methods of treating and/or reducing the likelihood of a Staphylococcus infection by administering a composition of the invention.

Abstract translation: 本发明涉及来自金黄色葡萄球菌的烯醇化酶蛋白质的肽以及编码该肽的核酸和核酸序列同系物。 本发明还涉及一种组合物，特别是金黄色葡萄球菌疫苗，其包含一种或多种本文所述的烯醇化酶或其能够产生诱导保护性抗体应答或调理吞噬活性的免疫应答的片段，衍生物或变体 人中性粒细胞用于金黄色葡萄球菌。 本发明还包括通过施用本发明的组合物来治疗和/或降低葡萄球菌感染的可能性的方法。

公开(公告)号：US09376487B2

公开(公告)日：2016-06-28

申请号：US14413939

申请日：2013-07-09

Applicant: Merck Sharp & Dohme Corp.

Inventor： Tessie B. McNeely ,  Leslie Cope ,  Gregory D. Pancari ,  Amita Joshi

IPC: A61K39/085 ,  C07K16/12 ,  C07K14/31 ,  A61K39/00

CPC classification number: C07K16/1271 ,  A61K39/085 ,  A61K2039/55505 ,  C07K14/31 ,  C07K2317/24

Abstract: The present invention relates to methods of inducing an immune response to Staphylococcus comprising administering a composition comprising an SA2493-related polypeptide from Staphylococcus aureus as well as derivatives or fragments thereof. The present invention also encompasses methods of treating and/or reducing the likelihood of a Staphylococcus infection by administering a composition comprising an SA2493-related polypeptide or an antibody that specifically binds to an SA2493 polypeptide, derivative or fragments thereof. Compositions administered in the methods of the invention can include one or more additional antigens including, but not limited to, IsdB. Compositions used to practice the methods of the invention are also encompassed.

Abstract translation: 本发明涉及诱导对葡萄球菌的免疫应答的方法，其包括从金黄色葡萄球菌及其衍生物或片段施用包含SA2493相关多肽的组合物。 本发明还包括通过施用包含与SA2493多肽或其衍生物或片段特异性结合的SA2493相关多肽或抗体的组合物来治疗和/或降低葡萄球菌感染的可能性的方法。 在本发明的方法中施用的组合物可以包括一种或多种另外的抗原，包括但不限于IsdB。 也包括用于实施本发明方法的组合物。

公开(公告)号：US09376474B1

公开(公告)日：2016-06-28

申请号：US14970610

申请日：2015-12-16

Applicant: EMD Millipore Corporation

Inventor： Shari Spector ,  Robert Smith ,  Joe Orlando ,  Nanying Bian

IPC: C07K14/31 ,  C07K1/22 ,  C07K16/12

CPC classification number: C07K14/31 ,  B01D15/3809 ,  B01J20/286 ,  B01J20/3272 ,  B01J20/3274 ,  C07K1/22 ,  C07K16/1271 ,  C07K2319/21

Abstract: The present invention relates to chromatography matrices including ligands based on one or more domains of immunoglobulin-binding proteins such as, Staphylococcus aureus Protein A (SpA), as well as methods of using the same.

公开(公告)号：US09315554B2

公开(公告)日：2016-04-19

申请号：US14466514

申请日：2014-08-22

Applicant: The University of Chicago

Inventor： Olaf Schneewind ,  Alice G. Cheng ,  Dominique M. Missiakas ,  Hwan Keun Kim

IPC: C07K14/31 ,  A61K39/085 ,  C07K16/12

CPC classification number: C07K14/31 ,  A61K39/085 ,  A61K2039/57 ,  C07K16/1271

Abstract: The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. The invention provides methods and compositions for stimulating an immune response against the bacteria. In certain embodiments, the methods and compositions involve a non-toxigenic Protein A (SpA) variant.

Abstract translation: 本发明涉及用于治疗或预防细菌感染，特别是葡萄球菌感染的方法和组合物。 本发明提供了刺激针对细菌的免疫应答的方法和组合物。 在某些实施方案中，所述方法和组合物涉及非产毒蛋白A（SpA）变体。

公开(公告)号：US09309299B2

公开(公告)日：2016-04-12

申请号：US14753101

申请日：2015-06-29

Applicant: SPIBER TECHNOLOGIES AB

Inventor： My Hedhammar ,  Jan Johansson ,  Anna Rising ,  Per Åke Nygren

IPC: C07K14/435 ,  A61K47/48 ,  B01D15/38 ,  B01J20/281 ,  C07K16/06 ,  B01D15/20 ,  C07D495/04 ,  C07K14/31 ,  C07K14/76 ,  C12N5/00

CPC classification number: C07K14/43518 ,  B01D15/20 ,  B01D15/3804 ,  B01D15/3809 ,  B01D15/3823 ,  B01J20/281 ,  C07D495/04 ,  C07K14/31 ,  C07K14/76 ,  C07K16/065 ,  C07K2319/01 ,  C07K2319/21 ,  C07K2319/22 ,  C07K2319/70 ,  C07K2319/705 ,  C12N5/0068 ,  C12N2533/50 ,  Y10S210/905

Abstract: A protein structure capable of selective interaction with an organic target is provided. The protein structure is a polymer comprising as a repeating structural unit a recombinant fusion protein that is capable of selective interaction with the organic target. The fusion protein is comprising the moieties B, REP and CT, and optionally NT. B is a non-spidroin moiety of more than 30 amino acid residues, which provides the capacity of selective interaction with the organic target. REP is a moiety of from 70 to 300 amino acid residues and is derived from the repetitive fragment of a spider silk protein. CT is a moiety of from 70 to 120 amino acid residues and is derived from the C-terminal fragment of a spider silk protein. NT is an optional moiety of from 100 to 160 amino acid residues and is derived from the N-terminal fragment of a spider silk protein. The fusion protein and protein structure thereof is useful as an affinity medium and a cell scaffold material.

公开(公告)号：US09290549B2

公开(公告)日：2016-03-22

申请号：US14164519

申请日：2014-01-27

Applicant: GE HEALTHCARE BIO-SCIENCES AB

Inventor： Martin Hall ,  Sture Larsson ,  Andreas Muranyi ,  Gustav Rodrigo ,  Jinyu Zou ,  Per-Mikael Aberg

IPC: C07K17/00 ,  C07K14/31 ,  B01D15/38 ,  B01J20/286 ,  C07K1/22 ,  B01J20/32 ,  C07K16/00

CPC classification number: B01J20/24 ,  B01D15/3809 ,  B01J20/28019 ,  B01J20/285 ,  B01J20/286 ,  B01J20/289 ,  B01J20/3212 ,  B01J20/3219 ,  B01J20/3274 ,  B01J20/3293 ,  B01J2220/52 ,  B01J2220/54 ,  C07K1/22 ,  C07K14/31 ,  C07K16/00 ,  C07K17/00 ,  C07K17/10 ,  C07K2317/55

Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates to a process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.

Abstract translation: 本发明涉及一种色谱配体，其包含来自葡萄球菌蛋白A（SpA）的结构域C，或其功能片段或变体。 色谱配体具有在现场（CIP）条件下耐受苛刻清洁的有利能力，并且能够结合抗体的Fab片段。 配体可以具有末端偶联基团，例如精氨酸或半胱氨酸，以促进其与不溶性载体例如珠粒或膜的偶联。 本发明还涉及在分离抗体中使用配体的方法以及可以包括洗涤步骤和/或用碱再生的纯化方案。